Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1Phase 1/2 1

Status

Recruiting 2Suspended 1

Sponsor Class

INDUSTRY 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 3Head & Neck 3Gynecologic 3Thoracic 2Plasma cell 2Lymphoid 2Breast 2Other solid neoplasm 1Other hematologic neoplasm 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Neoplasm Metastasis 2Neoplasms 1

Interventions

Specimen Handling 17Biopsy 16Magnetic Resonance Spectroscopy 10pembrolizumab 9Paclitaxel 6atezolizumab 5Standard of Care 5Bevacizumab 5trastuzumab deruxtecan 3ipatasertib 3durvalumab 3X-Rays 3Taxes 3Radiotherapy 3Exercise 3Cetuximab 3Carboplatin 3Capecitabine 3nilotinib 2inavolisib 2dostarlimab 2cabozantinib 2Tiragolumab 2Radiosurgery 2Radiation 2Practice Guidelines as Topic 2Pemetrexed 2Oxaliplatin 2Nivolumab 2Leucovorin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
ipatasertib × Tumor-Agnostic × 30 days × Clear all
NCT05554380 2026-05-22

Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial

National Cancer Institute (NCI)

Phase 2 Suspended
33 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT05862285 2026-05-12

UmbrellaMAX

Hoffmann-La Roche

Phase 3 Recruiting
100 enrolled
Tumor-Agnostic

Neoplasms

NCT04802759 2026-05-11

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

Hoffmann-La Roche

Phase 1/2 Recruiting
316 enrolled
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡